Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03372980
Other study ID # ARSBTA
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 2016
Est. completion date December 2026

Study information

Verified date April 2022
Source Beijing Institute of Heart, Lung and Blood Vessel Diseases
Contact Yuan WANG, PhD
Phone 86-010-64456169
Email wangyuan980510@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Takayasu arteritis is a chronic vasculitis mainly involving the aorta and its main branches such as the brachiocephalic, carotid, subclavian, vertebral, and renal arteries, as well as the coronary and pulmonary arteries. Inflammation causes segments of the vessels to become narrowed, blocked, or even stretched, possibly resulting in aneurysms. The disease is very rare but most commonly occurs in young Asian women. However, there is a considerable lack of understanding of the disease mechanism of Takayasu arteritis. Initially, the disease remains clinically silent (or remains undetected) until the patients present with vascular occlusion. Additionally, many individuals with Takayasu arteritis, however, have no apparent symptoms despite disease activity. Therefore, biomarkers for diagnosis and monitor disease activity in individuals with Takayasu arteritis are needed. In this study, the investigators therefore to use different methods to identify new biomarkers for diagnosing or monitoring the disease activity in individuals with Takayasu arteritis. These biomarkers may provide valuable insights into the underlying biochemical processes and aid the understanding of the pathophysiology of this disease.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date December 2026
Est. primary completion date December 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Retrospective Inclusion Criteria: Subjects who met the American College of Rheumatology 1990 classification criteria for Takayasu arteritis: 1. Age of onset =40 years, 2. Claudication of upper or lower extremities, 3. Decreased pulsation of 1 or both brachial arteries, 4. Difference of = 10 mmHg in systolic blood pressure between arms, 5. Bruit over subclavian arteries or aorta, 6. *Arteriographic evidence showing a branch of the aorta stenosis or occlusion. Meeting more than 3 of 6 criteria suggests the diagnosis of Takayasu arteritis. *Angiography in this study was replaced by vascular magnetic resonance angiography(MRA)or computed tomography angiography(CTA). Exclusion Criteria: 1. Arteriographic lesions that could be entirely due to atherosclerosis, 2. Suffer from other autoimmune diseases (eg, ANCA-associated vasculitis, systemic lupus erythematosus, etc.) besides Takayasu arteritis, 3. Cogan's syndrome, 4. Behcet's disease, 5. Subjects with any serious acute or chronic infection, 6. Giant cell arteritis (large vessel vasculitis and at least 50 years old) or other infectious forms of large vessel vasculitis. Prospective Inclusion Criteria: Subjects with initial suspicion of having Takayasu arteritis or patients with Takayasu arteritis need assessment of disease activity were prospectively enrolled. Exclusion Criteria: 1. Patients without image studies. 2. Patients with confirmed other autoimmune diseases (eg, ANCA-associated vasculitis, systemic lupus erythematosus, etc.)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Beijing Anzhen Hospital Beijing Beijing

Sponsors (3)

Lead Sponsor Collaborator
Beijing Institute of Heart, Lung and Blood Vessel Diseases Peking University People's Hospital, Shanghai Zhongshan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnosis of each participant Participant with Takayasu arteritis had image information from vascular magnetic resonance angiography (MRA) or computed tomography angiography (CTA) to confirm the final diagnosis. These data is collected from the cases' medical record in an average of 3 month after the sample recruiting.
Primary Disease activity of each participant Criteria for Disease Activity:Criteria for active disease are detection of new vascular lesion or lesions in arteries on vascular Imaging in participants who had undergone magnetic resonance angiography (MRA) or computed tomography angiography (CTA) examination in the month before evaluation, or at least 2 of the following: 1) new onset of carotodynia or pain over large vessels, 2) transient ischemic episodes not attributable to other factors, 3) new bruit or new asymmetry in pulses or blood pressure determination, 4) ischemic symptoms (including new-onset claudication), and 5) fever in absence of infection.
Criteria defined inactive disease: 1) absence of the features of active disease for at least the previous 3 months; 2) absence of new vascular lesions and stability or improvement of previous vascular lesion or lesions on an imaging study performed up to 1 month before evaluation.
These data is collected from the cases' medical record or during follow-up visit in an average of 6 month after the sample recruiting.
See also
  Status Clinical Trial Phase
Recruiting NCT02257866 - Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Completed NCT02190916 - Vasculitis Illness Perception (VIP) Study N/A
Recruiting NCT01241305 - One-Time DNA Study for Vasculitis
Completed NCT02190942 - VCRC Patient Contact Registry Patient-Reported Data Validation Study
Recruiting NCT03494062 - Exercise in Juvenile Takayasu Disease N/A
Recruiting NCT02457585 - Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis Phase 2
Completed NCT02190929 - Educational Needs of Patients With Systemic Vasculitis N/A
Completed NCT02476292 - Impact of Vasculitis on Employment and Income N/A
Completed NCT02176070 - Reproductive Health in Men and Women With Vasculitis N/A
Completed NCT00556439 - Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis Phase 2
Completed NCT01795456 - Carotid Artery Neovascularization in Takayasu's and Giant Cell Arteritis N/A
Completed NCT00315471 - Determining Disease Activity Biomarkers in Individuals With Takayasu's Arteritis